What are the approved human formulations and dosages of ivermectin and their approved uses?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Ivermectin for humans is approved in oral and topical prescription formulations to treat specific parasitic infections and certain skin conditions; the drug is not FDA-authorized for COVID-19 and veterinary products differ materially and can be dangerous if used by people [1] [2] [3]. Standard human dosing is weight‑based for oral use (typically in the range of 150–200 micrograms per kilogram for common indications), while topical products are available by prescription for conditions such as rosacea and head lice, with precise regimens varying by formulation and diagnosis [4] [1].
1. What formulations are approved for people: tablets and prescription topicals
For human patients, ivermectin is available as oral tablets approved to treat intestinal and tissue parasitic infections, and as topical prescription preparations used for certain external parasites and inflammatory skin conditions (head lice, scabies in some scenarios, and rosacea) rather than as over‑the‑counter veterinary products intended for animals [1] [5] [2].
2. Approved oral dosing: weight‑based antiparasitic regimens
Clinical guidance and drug‑reference summaries report that oral ivermectin dosing for approved parasitic infections is weight‑based; commonly cited regimens for human use fall in the neighbourhood of 150–200 micrograms per kilogram as a single dose for many intestinal helminth infections, with retreatment intervals and repeated dosing determined by the specific parasite (for example, repeated or periodic dosing is used in onchocerciasis because ivermectin does not kill adult worms) [4] [2]. Drugs.com provides detailed, diagnosis‑specific dosing schedules and notes the need for retreatment or alternative measures in infections where adult parasites persist [4].
3. Topical products and dermatologic dosing: prescription only
Topical ivermectin formulations exist as prescription treatments for some skin conditions (including rosacea) and for certain external parasitic problems; these preparations are dosed according to the product label and clinical judgment and are distinct from oral tablets in indication and pharmacokinetics [1]. Medical News Today and the FDA both emphasize that topical formulations are part of the approved human armamentarium but must be used as prescribed; off‑label topical use should follow a clinician’s direction [6] [1].
4. What ivermectin is officially approved to treat
Regulatory and public‑health sources list the primary approved human uses as treatment of specific parasitic worm infections — notably strongyloidiasis (threadworm) and onchocerciasis (river blindness) — and certain external parasitic or dermatologic indications covered by topical products; these are the indications on which safety and efficacy determinations have been based [2] [1] [3].
5. What is not approved: COVID‑19 and veterinary products
The FDA has not authorized or approved ivermectin to prevent or treat COVID‑19 and has explicitly warned against self‑medicating with animal formulations because those products are formulated differently and can be highly concentrated or contain dangerous excipients; poison control and public‑health agencies documented increased human exposures and harms during the pandemic when people took veterinary products or inappropriate doses [1] [3] [5].
6. Practical caveats, off‑label prescribing, and evolving policy context
Physicians legally may prescribe approved human drugs for unapproved (off‑label) uses when judged appropriate, but major medical societies and regulators discourage use of ivermectin for COVID‑19 because clinical trial evidence has not demonstrated benefit and safety concerns exist; concurrently, some U.S. states have moved to make human ivermectin easier to obtain or to shield dispensing pharmacists, a policy trend that complicates clinical stewardship and raises public‑health debate [1] [7] [8].